secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001785530-25-000020
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q2 net loss $18M; WTX-124 data on track for Q4 2025
-------------------------------------------------------------------------

- Cash $77.6M as of June 30, 2025, providing runway into Q4 2026.
- Net loss $18.0M for Q2 2025 vs $17.2M in Q2 2024; R&D $13.1M, G&A $4.4M.
- WTX-124 Phase 1/1b interim data expected Q4 2025 in melanoma and renal cell carcinoma.
- Planning FDA engagement in H2 2025 to discuss registrational pathway for cutaneous melanoma.
- New candidate WTX-1011 (anti-STEAP1 T-cell engager) announced; additional candidate expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/0001785530-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/howl-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001785530-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer